Dil B Begum

TL;DR: The understanding of genetic events in myeloma is refined and clinically relevant mutations that may be used to better stratify patients at presentation are identified to generate an international staging system mutation score that can identify a high-risk population of patients who experience relapse and die prematurely.

TL;DR: The APOBEC mutational signature seen in myeloma is associated with poor prognosis primary and secondary translocations and the molecular mechanisms involved in generating them.

TL;DR: This study confirms that myeloma subclones exhibit different survival properties during treatment or mouse engraftment, and concludes that clonal diversity combined with varying selective pressures is the essential foundation for tumor progression and treatment resistance in Myeloma.

TL;DR: Profiling multiple genetic lesions can identify MM patients likely to relapse early allowing stratification of treatment, and defines distinct sub-groups of hyperdiploid MM.

TL;DR: It is postulate that translocation breakpoints near MYC result in colocalization of the gene with superenhancers from loci, which are important in the development of the cell type in which they occur, resulting in increased expression of MYC and an aggressive disease phenotype.